Growth Hormone Axis Research
CJC-1295 + Ipamorelin Stack — GHRH + GHRP Growth Hormone Peptide Stack
Pairs two different growth hormone signals — a GHRH analog and a GHRP. Laid out as two individual vials so each amount can be adjusted independently.
Total program: 12 weeks · 2 individual vials
Why these peptides are researched together
Growth hormone release is controlled by two separate pituitary signals. CJC-1295 acts on the GHRH receptor (the “release” signal), and Ipamorelin acts on the ghrelin receptor (GHSR). Human research on GHRH plus GHRP combinations reports a larger growth hormone pulse than either signal alone, which is the basis for pairing them. Ipamorelin is chosen as the GHRP because it shows little effect on cortisol or prolactin.
Each peptide at a glance
- CJC-1295 (no DAC): GHRH analog studied for pulsatile growth hormone release.
- Ipamorelin: Selective ghrelin-receptor agonist (GHRP) studied for GH release with minimal cortisol/prolactin change.
How the schedules fit together
Both are drawn once daily before bed, typically on an empty stomach, so they line up at the same time each night. In this stack both run 8–12 weeks daily, followed by Ipamorelin's 4-week break. The CJC-1295 chart on its own lists 8–16 weeks; here it is aligned to the 12-week Ipamorelin window so the two start and finish together.
What the research shows
Human studies show CJC-1295 raises GH and IGF-1; Ipamorelin is documented as a selective GH secretagogue.
Still unproven
Direct outcome data for the combination is lacking.
FAQs
What is the CJC-1295 + Ipamorelin Stack?
Pairs two different growth hormone signals — a GHRH analog and a GHRP. Laid out as two individual vials so each amount can be adjusted independently.
What's in the CJC-1295 + Ipamorelin Stack?
The CJC-1295 + Ipamorelin Stack combines CJC-1295 and Ipamorelin, each in its own vial. CJC-1295: GHRH analog studied for pulsatile growth hormone release. Ipamorelin: Selective ghrelin-receptor agonist (GHRP) studied for GH release with minimal cortisol/prolactin change.
What does the CJC-1295 + Ipamorelin Stack do?
Growth hormone release is controlled by two separate pituitary signals. CJC-1295 acts on the GHRH receptor (the “release” signal), and Ipamorelin acts on the ghrelin receptor (GHSR). Human research on GHRH plus GHRP combinations reports a larger growth hormone pulse than either signal alone, which is the basis for pairing them. Ipamorelin is chosen as the GHRP because it shows little effect on cortisol or prolactin.
What is the CJC-1295 + Ipamorelin Stack dosage?
The amounts for each peptide are listed week by week in the dosing table on this page, taken from each peptide's full dosing chart, with units on a 100-unit syringe and exact vial counts for the full 12-week program.
How long is the CJC-1295 + Ipamorelin Stack?
The CJC-1295 + Ipamorelin Stack is laid out as a 12-week research program. Both are drawn once daily before bed, typically on an empty stomach, so they line up at the same time each night. In this stack both run 8–12 weeks daily, followed by Ipamorelin's 4-week break. The CJC-1295 chart on its own lists 8–16 weeks; here it is aligned to the 12-week Ipamorelin window so the two start and finish together.
What does research show about the CJC-1295 + Ipamorelin Stack?
Human studies show CJC-1295 raises GH and IGF-1; Ipamorelin is documented as a selective GH secretagogue. Still unproven: Direct outcome data for the combination is lacking.
Sources
- Dr. Henry Sobo, MD — Anti-Aging Peptide Stack Guide, Part 3 of 11
- Meto — The 7 Most Popular Peptide Stacks: What the Science Actually Says
- PubMed — CJC-1295 GH and IGF-1 study
- PubMed — Ipamorelin selective GH secretagogue
Other peptide stacks
- Wolverine Stack
- GLOW Peptide Stack
- KLOW Peptide Stack
- Tesamorelin + Ipamorelin Stack
- Semax + Selank + NAD+ Stack
- Mitochondrial Peptide Stack
- Tirzepatide + AOD-9604 Stack
- AOD-9604 + MOTS-c Stack
- Epitalon + Pinealon Stack
Educational research reference only. Not medical advice or individualized guidance.